Objectives: To assess the efficacy and safety of modified Xiaoyao San (XYS) for treating Perimenopausal syndrome (PMS). Methods: Literature searches were carried out on PubMed, Cochrane Library, CNKI Database, Chinese Biomedical Literature Database, Wan Fang Database, and VIP Database up to December 2018. Hand search for further references was conducted. Study selection, data extraction, quality assessment, and data analyses were performed as request of the Cochrane standards. Results: Nine publications in total were suitable for inclusion. There was evidence that modified XYS was tested to be more effective in improving overall symptoms compared with HRT (odds ratio 3.50, 95% CI 2.56 to 4.78). Whereas HRT was more sensitive and direct in decreasing FSH (WMD 6.69, 95% CI 5.60 to 9.52) and LH (WMD 7.00, 95% CI, 5.75 to 8.25) in comparison with XYS group. It was also strongly supported that XYS had less adverse effect than HRT (odds ratio 0.07, 95% CI 0.05 to 0.10). Conclusion: Modified XYS might be more effective and safer in treatment of perimenopausal syndrome. However, due to poor methodological quality in the majority of included studies, the potential benefit and safety about XYS need to be confirmed in rigorously designed, multi-centre, and large-scale trials.
drome, and if it is really safer than HRT? With a view to answering these questions, the meta-analysis of randomized controlled trials evaluates the effects and safety of modified XYS in treating patients with PMS compared with HRT.
Methods

Search Strategy
Comprehensive literature searches were conducted in PubMed 
Study Selection
Studies were considered to be eligible for inclusion if they met all of the following criteria: 1) Patients included in the study were diagnosed with Perimenopausal syndromes; 2) The study was performed as a randomized controlled trial (RCT); 3) XYS (all the modified Xiaoyao San formula were included) was compared with HRT; 4) Criteria for successful treatment were clearly clarified, and treatment success was not only measured in terms of the scores of Kupperman Index (KI) or Serum FSH, E2, HL, the criteria "recover, significant effective, effective, or not effective" was also included in the outcome measurement; 5) Treatment lasted for 3 weeks or more. For the meta-analysis, the terms of "patients without symptoms," Duplicated publications reporting the same groups of participants were excluded.
Data Extraction
Two researchers abstracted the data from the studies independently to avoid bias in the data abstraction process. All data were checked for internal consistency, and disagreements were resolved by discussion with other investigators. Details abstracted from the studies included the name of the first author, location of the report, year of publication, age of subjects in the XYS or HRT group, number of participants in each group, dosage of each intervention, duration of treatment, adverse effect and follow-up situation. Quality assessment of randomized controlled trials: sequence generation, allocation concealment, blinding of participants personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. 
Data Analysis
The statistical package Review Manager Software (RevMan 5.3) was used for data analyses, which was provided by The Cochrane Collaboration. Dichotomous data were presented as odds ratio (OR) and continuous outcomes as mean difference (MD), both with 95% confidence interval (CI). Meta-analysis was performed if the intervention, control, and outcome were the same or similar. The chi-squared test for heterogeneity was performed, and heterogeneity was presented as significant when I2 is over 50% or P < 0.1. Random effect model was used for the meta-analysis if there was significant heterogeneity; otherwise fixed effect model was used. 
Results
Search Results
Characteristics and Methodological Quality of Included Trials
The risk of bias assessment in the trials was summarized in Figure 2 . A low risk of bias was found across studies for blinding of outcome assessment and incomplete outcome data, selective reporting. Two publications were of randomization procedures generated by random number tables [24] [25]. None of them have mentioned allocation concealment and double blind. One of them using serum hormone as outcomes, which would not be influenced by Measurement bias, was rated as low risk [24] . Four trials were considered as high risks ascribing to using decoction of herbal medicine in experiment and hardly achieving double blind [25] [29] . Among all trials, the characteristics of participants in different treatment groups were similar at baseline (age, sex, race, and disease course). Journal of Biosciences and Medicines 
Analysis of XYS Formula
Four kinds of XYS formula were used as intervention in experiment group. Three trials used fixed XYW throughout the treatment [21] [22] [23] , one of them administered together with ginger water [22] . Four trials XYW was modified and combined with different Chinese herbs on the basis of syndrome differentiation [24] - [28] , one used JWXYS [28] and one used DZXYS [29] . Interestingly we found JWXYS in the trial [28] was actually simply DZXYS. In Table 2 , we listed the Chinese herbs in every prescription. Bupleurum root (Chai Hu), Chinese Angelica Root (Dang Gui), White Peony Root (Bai Shao) showed up most often, and used in every prescription. The preparation formulation was divided into pills and decoction. Figure 3 showed the OR and summary OR for each trial. The summary OR was 3.50 (95% CI: 2.56 -4.78, P < 0.00001), indicating that PMS patients with XYS treatment had more than 3-fold higher probability of symptom relief compared to treatment with HRT. No substantial heterogeneity was found (P = 0.29, I2 = 18%).
Some Common Mistakes
Serum FSH, E2, LH
Only one of the studies [24] performed the test of serum sexual hormone like FSH, E2, LH as outcomes. We found from the article that both the experiment group and control group could obviously decrease serum FSH and LH, while both had a tendency to increase serum E2, but no statistical significance existed. However, from the Meta-analysis it turned out that HRT showed a significant improvement in reducing FSH and LH by contrast with modified XYS. (FSH: WMD, 6.69; 95% CI, 5.60 to 9.52; P < 0.00001, Figure 4 [29] . One of them reported no adverse effects during treatment of both groups [24] . Three trials declared no serious adverse events found in modified XYS group; whereas the patients experienced HRT had suffered from gastroenteric adverse reaction including nausea and vomiting [21] [28] [29] . Two trials reported a variety of symptoms developed such as nausea, headache, edema, leukorrhagia, and abdominal distention, colporrhagia in both modified XYS groups and HRT groups [22] [26] . Meta-analysis robustly supported that XYS showed less side effects than HRT, and had statistical significance. (OR 0.07; 95%, CI 0.05 -0.10; P < 0.00001, Figure 5) 
Adverse Events
Discussion
The results of the present meta-analysis revealed that modified Xiaoyao San was superior to hormone replacement therapy in improving comprehensive PMS symptoms (OR 3.50; point; 95% CI: 2.56 -4.78). The study also demonstrated that adverse events after treated with XYS were significantly lower than with HRT supported by Meta-analysis (OR 0.07; 95%, CI 0.05 -0.10).
In TCM, the basic mechanism of Perimenopausal syndrome is deficiency of the kidney. However, effective treatment cannot be guaranteed only by nourishing kidney in treating PMS. The reason would be that PMS is intimately related to the dysfunction of Liver. Liver depression and Qi stagnation leading to transformation of Fire and disturbing cardiac sprit, or invasion of Liver Qi into the Spleen and Stomach are also crucial mechanism of PMS [30] [31] [32] .
In accordance with the mechanism of PMS, herbs of modified Xiaoyao San in the trials included can be divided into several groups. The first group is composed of Adix Bupleuri (Chai Hu), Chinese Angelica and White Peony Root (Bai Shao), which plays the main role in whole formula. Adix Bupleuri (Chai Hu)
contributes to Soothing liver and relieving depression, the experiment stated that the methanolic Bupleurum falcatum (BFM) extract had dose-dependent possibility of antidepressant-like activity valuable to alternative therapy for depression and that the mechanism of action might involve the serotonergic and noradrenergic systems [33] . Chinese Angelica (Dang Gui) can be used for tonifying and harmonizing blood, regulating menstruation to relieve pain. Biochemically, Angelica can promote hematopoietic function of bone marrow and spleen cells and significantly increase the number of hemoglobin and red blood cells [34] , can also potentiate the immune functions [35] . The function of White Peony rats [36] . And the modulation of the hypothalamic-pituitary-adrenal axis and up-regulation of serotonergic and noradrenergic systems might be important mechanisms underlying the antidepressant-like effects of paeoniflorin in CUS-treated rats [37] . A combination of these three herbs used most frequently in prescriptions was demonstrated to significantly soothes liver, nourish blood and regulate nutrient [38] . The second group, White Atractylodes Rhizome (Bai Zhu), Poria It can be affirmed that the safety of XYS appears satisfactory. It is noteworthy XYS has been approved as a non-prescription formula by State Food and Drug Administration (SFDA), which reinforce validity about the safety of XYS. The explanation of the encouraging safety might be that the multi-target effect of herbal preparations may produce relatively low concentration of active ingredients [40] . As we mentioned above that majority of women with PMS preferred non-pharmacological interventions to HRT [17] [18] [19] , XYS can be recommended for its distinguished safety.
From the meta-analysis, hormone replacement therapy was more sensitive and direct than modified XYS in ameliorating the sexual hormone such as FSH and LH, but no statistically significant difference between two groups in increasing serum E2. Nevertheless, there was only one study involved, the result needs further clinical trials or laboratory bench studies to verify.
We should consider several limitations before accepting the findings of this ti-center, large sample, and cooperative studies were found, and most of the trials were of small sample size, and no studies estimated the sample size. Most of the studies did not report about allocation concealment process, which might have created potential selection bias. And it's been difficult to implement double blind for distinct intervention dosage forms between two groups. Therefore, measurement bias was always of concern. Second, given the fact that all of the nine trials included were in Chinese, the publication bias possibly existed. Third, different modified Xiaoyao prescriptions and various forms and dosage were used in the trials, medication frequency were from once a day to three times a day, and the treatment duration varied from 4 weeks to 12 weeks.
Conclusion
In conclusion, the results of the present paper preliminarily confirm that modified Xiaoyao San is more efficacious and has less adverse events compared to hormone replacement therapy in treatment of perimenopausal syndrome. However, considering the general quality of the reports was moderate; the effectiveness and safety of Xiaoyao San prescription need further rigorous trials, multi-centre, large-scale, and transnational cooperative RCTs to prove.
